Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, placebo-controlled, parallel, multicenter study on extended VTE [venous thromboembolism] prophylaxis in acutely ill medical patients with prolonged immobilization

Next Previous
X
Search
Trial Profile

A double-blind, placebo-controlled, parallel, multicenter study on extended VTE [venous thromboembolism] prophylaxis in acutely ill medical patients with prolonged immobilization

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Sep 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enoxaparin sodium (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EXCLAIM
  • Sponsors Sanofi

    • Most Recent Events

    • 30 Aug 2017 Results of pooled data from four randomized trials (EXCLAIM, ADOPT, MAGELLAN, and APEX trials) assessing qualitatively and quantitatively risk-benefit profile of extended-duration pharmacologic prophylaxis using the bivariate analysis, were presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
    • 06 Jul 2010 Results published in Annals of internal medicine.
    • 06 Jul 2010 Results were published in a sanofi aventis media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top